COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
Completed · Phase 1/Phase 2
Conditions studied: Endometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer
In brief
This is a phase 1/2 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM701 in combination with BMS-986207 and nivolumab in patients with advanced solid tumors.
Key facts
- Study ID
- NCT04570839
- Run by
- Compugen Ltd
- People needed
- 48
- Starts
- 2020-08-31
- Expected to finish
- 2024-05-15
- Last updated by the study team
- 2024-07-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Chicago Medical Center — Chicago, Illinois, United States
- Johns Hopkins University Oncology Center. — Baltimore, Maryland, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- START Midwest. — Grand Rapids, Michigan, United States
- Columbia University — New York, New York, United States
- University of Pittsburgh Cancer Center. — Pittsburgh, Pennsylvania, United States
- The University of Tennessee WEST Cancer Center. — Memphis, Tennessee, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- The START Center for Cancer Care. — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.